Meerut Reporter

Multiple System Atrophy Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Multiple System Atrophy Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

September 15
21:14 2022
Multiple System Atrophy Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 20+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Multiple System Atrophy Overview

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by symptoms that affect the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. Formerly called Shy-Drager syndrome, olivopontocerebellar atrophy or striatonigral degeneration, MSA shares many Parkinson’s disease-like symptoms.

“Multiple System Atrophy Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market. 

The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Multiple System Atrophy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years. Multiple System Atrophy Key players such as – Inhibikase Therapeutics, Stealth Research programme, AskBioBioTherapeutics, AFFiRiS, Corestem, Brain Neurotherapy Bio, Inc., H. Lundbeck A/S, EmeraMed, Zambon SpA, Biohaven Pharmaceuticals, and others, are developing therapies for the Multiple System Atrophy treatment 
  • Multiple System Atrophy Emerging therapies such as – IKT-148009, SBT 272, CNS Gene Therapy, AFFITOPE PD01A and PD03A, CS10BR05, AAV2-GDNF gene therapy, Droxidopa, Emeramide, Safinamide, Verdiperstat, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years.   
  • In September 2018, Biohaven Pharmaceuticals entered into an exclusive, worldwide license agreement, through its subsidiary Biohaven Therapeutics Ltd., with AstraZeneca AB for the development commercialization rights to AZD3241, oral myeloperoxidase (MPO) inhibitor that AstraZeneca progressed through Phase 2 clinical trials.
  • In July 2019, Biohaven Pharmaceuticals initiated a Phase III randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of verdiperstat in approximately 300 patients with a clinical diagnosis of MSA between 40-80 years of age
  • In March 2020, verdiperstat by Biohaven Pharmaceuticals, received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of multiple system atrophy (MSA) 

 

Multiple System Atrophy Pipeline Therapeutics Assessment

  • Multiple System Atrophy Assessment by Product Type
  • Multiple System Atrophy By Stage and Product Type
  • Multiple System Atrophy Assessment by Route of Administration
  • Multiple System Atrophy By Stage and Route of Administration
  • Multiple System Atrophy Assessment by Molecule Type
  • Multiple System Atrophy by Stage and Molecule Type 

 

DelveInsight’s Multiple System Atrophy Report covers around 20+ products under different phases of clinical development like 

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include: 

  • IKT-148009: Inhibikase Therapeutics
  • SBT 272: Stealth Research programme
  • CNS Gene Therapy: AskBioBioTherapeutics
  • AFFITOPE PD01A and PD03A: AFFiRiS
  • CS10BR05: Corestem
  • AAV2-GDNF gene therapy: Brain Neurotherapy Bio, Inc.
  • Droxidopa: H. Lundbeck A/S
  • Emeramide: EmeraMed
  • Safinamide: Zambon SpA
  • Verdiperstat: Biohaven Pharmaceuticals

 

Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies

 

Multiple System Atrophy Pipeline Analysis:

The Multiple System Atrophy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Multiple System Atrophy treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
  • Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Assessment

 

Scope of Multiple System Atrophy Pipeline Drug Insight    

  • Coverage:  Global
  • Key Multiple System Atrophy Companies:  Inhibikase Therapeutics, Stealth Research programme, AskBioBioTherapeutics, AFFiRiS, Corestem, Brain Neurotherapy Bio, Inc., H. Lundbeck A/S, EmeraMed, Zambon SpA, Biohaven Pharmaceuticals, and others
  • Key Multiple System Atrophy Therapies:  IKT-148009, SBT 272, CNS Gene Therapy, AFFITOPE PD01A and PD03A, CS10BR05, AAV2-GDNF gene therapy, Droxidopa, Emeramide, Safinamide, Verdiperstat, and others
  • Multiple System Atrophy Therapeutic Assessment:  Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
  • Multiple System Atrophy Market Dynamics:  Multiple System Atrophy market drivers and Multiple System Atrophy market barriers 

Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials

Table of Contents

1

Multiple System Atrophy Report Introduction

2

Multiple System Atrophy Executive Summary

3

Multiple System Atrophy Overview

4

Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment

5

Multiple System Atrophy Pipeline Therapeutics

6

Multiple System Atrophy Late Stage Products (Phase II/III)

7

Multiple System Atrophy Mid Stage Products (Phase II)

8

Multiple System Atrophy Early Stage Products (Phase I)

9

Multiple System Atrophy Preclinical Stage Products

10

Multiple System Atrophy Therapeutics Assessment

11

Multiple System Atrophy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Multiple System Atrophy Key Companies

14

Multiple System Atrophy Key Products

15

Multiple System Atrophy Unmet Needs

16 

Multiple System Atrophy Market Drivers and Barriers

17

Multiple System Atrophy Future Perspectives and Conclusion

18

Multiple System Atrophy Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/